Loading…
Loading…
EQUITY / NASDAQ · XNCM
Dogwood Therapeutics Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗1.35 USD
Observed: 09/30/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
09/30/2026 · 1.35 USD · Volume 34,383
21 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Operating profit | -14,063,525 USD | -3,923,115 USD | — |
| Net income | -11,529,609 USD | -3,807,353 USD | — |
| Cash and cash equivalents | 9,610,033 USD | — | — |
| Total liabilities | 12,129,372 USD | — | — |
| Total equity | 68,366,108 USD | 6,878,599 USD | +893.90% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 9,610,033 USD | — | — | 6,524,744 USD | 6,524,744 USD | 10,126,710 USD | — | — |
| Net incomeIncome statement | -11,529,609 USD | -16,516,223 USD | -4,986,614 USD | — | -34,257,370 USD | -15,744,616 USD | -30,476,921 USD | -3,807,353 USD |
| Operating profitIncome statement | -14,063,525 USD | -19,139,891 USD | — | — | -27,968,445 USD | -15,809,125 USD | -24,162,166 USD | -3,923,115 USD |
| Total assetsBalance sheet | 80,495,480 USD | — | — | 90,171,237 USD | 90,171,237 USD | 91,992,613 USD | — | — |
| Total equityBalance sheet | 68,366,108 USD | — | 80,623,352 USD | 74,896,867 USD | 74,896,867 USD | 7,258,152 USD | — | 6,878,599 USD |
| Total liabilitiesBalance sheet | 12,129,372 USD | — | — | 15,274,370 USD | 15,274,370 USD | 14,607,504 USD | — | — |
| Financing cash flowCash flow statement | — | 11,291,348 USD | — | — | 7,284,806 USD | — | 7,252,245 USD | — |
| Operating cash flowCash flow statement | — | -8,198,274 USD | — | — | -15,618,651 USD | — | -11,981,464 USD | — |
| Report source | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 03/18/2026 | Open report ↗ Published: 11/07/2025 | Open report ↗ Published: 11/07/2025 | Open report ↗ Published: 08/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.